Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 03, 2025 | June 05, 2025 |
| PFIZER INCPFE · Entity 2863 | Director | April 23, 2015 | April 24, 2015 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 03, 2023 | January 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date June 03, 2025 · Filed June 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,886,576 |
Reported balance
After 2025-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-03 · Grant · Acquired 6,037 · Balance 1,886,576 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,037 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.93 · Expires 2035-06-03 | Direct | 18,111 |
Reported balance
After 2025-06-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-06-03 · Grant · Acquired 18,111 · Balance 18,111 F6: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
| Common StockSEC Table I · non-derivative | IndirectThe Tessier-Lavigne/Hynes Irrevocable Trust 1 | 78,848 |
Reported balance
Holding disclosure · report date 2025-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 78,848 F3: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectThe Tessier-Lavigne/Hynes Irrevocable Trust 2 | 79,173 |
Reported balance
Holding disclosure · report date 2025-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 79,173 F4: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectThe Tessier-Lavigne/Hynes Irrevocable Trust 3 | 78,848 |
Reported balance
Holding disclosure · report date 2025-06-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 78,848 F5: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 6,037 unvested RSUs.
F3: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee.
F4: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee.
F5: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee.
F6: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
PFIZER INC
Report date April 23, 2015 · Filed April 24, 2015
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 29,099.964 |
Reported balance
After 2015-04-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2015-04-23 · Grant · Acquired 4,595.588 · Balance 29,099.964 F1: Each unit represents one phantom share of common stock. F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.
REGENERON PHARMACEUTICALS, INC.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,434 |
Reported balance
After 2023-01-03 transaction · row 1
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 165 · Balance 2,434 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $725.89 · Expires 2033-01-03 | Direct | 1,929 |
Reported balance
After 2023-01-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-03 · Grant · Acquired 1,929 · Balance 1,929 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2022 Filed Mar 23, 2022 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 7,439 | $380.95 | $2,833,887.05 |
DisclosureSEC source: 0001708138-22-000027 · edgardoc.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001708138-22-000020 · edgardoc.xml · derivative · entry 6 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,830 | $680.00 | $5,324,400.00 |
DisclosureSEC source: 0001708138-22-000020 · edgardoc.xml · nonDerivative · entry 4 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,269 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 7,830 | $376.69 | $2,949,482.70 |
DisclosureSEC source: 0001708138-22-000020 · edgardoc.xml · nonDerivative · entry 3 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,361 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001708138-22-000020 · edgardoc.xml · derivative · entry 5 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,361 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,361 | $675.00 | $2,943,675.00 |
DisclosureSEC source: 0001708138-22-000020 · edgardoc.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,269 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 4,361 | $374.12 | $1,631,537.32 |
DisclosureSEC source: 0001708138-22-000020 · edgardoc.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,707 | $0.00 Strike: $625.60 | $0.00 |
DisclosureSEC source: 0001883850-22-000008 · edgardoc.xml · derivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,707 Underlying: Common Stock · 2,707 shares Expires 2032-01-03 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:23 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 191 | $0.00 | $0.00 |
DisclosureSEC source: 0001883850-22-000008 · edgardoc.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,269 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 30, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 800 | $45.72 | $36,576.00 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 16 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 3 Disclosed balance after: 78,848 F17 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.67 to $45.80 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F13 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee. Read SEC document |
| December 30, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 6,002 | $45.31 | $271,950.62 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 15 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 3 Disclosed balance after: 79,648 F16 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.65 to $45.62 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F13 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee. Read SEC document |
| December 30, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 900 | $45.71 | $41,139.00 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 11 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 2 Disclosed balance after: 79,173 F12 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.66 to $45.77 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F8 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee. Read SEC document |
| December 30, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 5,625 | $45.31 | $254,868.75 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 10 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 2 Disclosed balance after: 80,073 F11 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.65 to $45.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F8 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee. Read SEC document |
| December 30, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,377 | $45.59 | $153,957.43 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 6 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 1 Disclosed balance after: 78,848 F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.42 to $45.81 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee. Read SEC document |
| December 30, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,343 | $45.13 | $150,869.59 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 5 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 1 Disclosed balance after: 82,225 F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.42 to $45.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee. Read SEC document |
| December 29, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 10,704 | $43.88 | $469,691.52 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 14 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 3 Disclosed balance after: 85,650 F15 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.50 to $44.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F13 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee. Read SEC document |
| December 29, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 10,700 | $43.87 | $469,409.00 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 9 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 2 Disclosed balance after: 85,698 F10 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.51 to $44.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F8 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee. Read SEC document |
| December 29, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 10,700 | $43.88 | $469,516.00 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 4 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 1 Disclosed balance after: 85,568 F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.50 to $44.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,646 | $44.37 | $161,773.02 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 13 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 3 Disclosed balance after: 96,354 F14 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.18 to $44.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F13 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,602 | $44.38 | $159,856.76 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 8 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 2 Disclosed balance after: 96,398 F9 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.19 to $44.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F8 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee. Read SEC document |
| December 28, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,732 | $44.37 | $165,588.84 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 3 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 1 Disclosed balance after: 96,268 F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.19 to $44.74 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee. Read SEC document |
| December 13, 2021 Filed Feb 18, 2022 01:25 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GiftCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-22-000043 · wf-form5_164514750112269.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,044,370 F1 · price: This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift. F2 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 22:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,784 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001237899-21-000027 · edgardoc.xml · derivative · entry 3 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,784 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 22:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,784 | $665.00 | $2,516,360.00 |
DisclosureSEC source: 0001237899-21-000027 · edgardoc.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,078 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 22:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 3,784 | $371.40 | $1,405,377.60 |
DisclosureSEC source: 0001237899-21-000027 · edgardoc.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| October 04, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 12 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 3 Disclosed balance after: 100,000 F1 · price: This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift. F13 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee. Read SEC document |
| October 04, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 7 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 2 Disclosed balance after: 100,000 F1 · price: This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift. F8 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee. Read SEC document |
| October 04, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Tessier-Lavigne/Hynes Irrevocable Trust 1 Disclosed balance after: 100,000 F1 · price: This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift. F3 · ownership.nature: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee. Read SEC document |
| October 04, 2021 Filed Dec 31, 2021 02:59 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GiftCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-21-000117 · wf-form4_164091956763788.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,244,370 F1 · price: This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift. F2 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,250 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · derivative · entry 23 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,250 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F17 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,250 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · derivative · entry 22 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F17 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,250 | $0.00 Strike: $273.67 | $0.00 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · derivative · entry 21 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 4,250 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F17 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 139 | $652.26 | $90,664.14 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 20 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,078 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 249 | $651.54 | $162,233.46 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 19 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,217 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · price: Represents volume-weighted average price of sales of 249 shares of Company stock on September 13, 2021 at prices ranging from $651.10 to $651.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 56 | $650.33 | $36,418.48 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 18 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,466 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 124 | $649.35 | $80,519.40 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 17 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,522 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · price: Represents volume-weighted average price of sales of 124 shares of Company stock on September 13, 2021 at prices ranging from $649.27 to $649.43. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 381 | $648.25 | $246,983.25 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 16 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,646 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 381 shares of Company stock on September 13, 2021 at prices ranging from $648.06 to $648.58. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 425 | $647.39 | $275,140.75 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 15 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,027 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 425 shares of Company stock on September 13, 2021 at prices ranging from $647.06 to $647.67. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 354 | $646.24 | $228,768.96 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 14 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,452 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 354 shares of Company stock on September 13, 2021 at prices ranging from $646.04 to $646.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 61 | $645.21 | $39,357.81 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 13 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,806 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 61 shares of Company stock on September 13, 2021 at prices ranging from $645.21 to $645.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 844 | $644.52 | $543,974.88 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 12 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,867 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 844 shares of Company stock on September 13, 2021 at prices ranging from $644.03 to $644.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,549 | $643.33 | $996,518.17 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 11 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,711 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 1,549 shares of Company stock on September 13, 2021 at prices ranging from $643.01 to $643.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,645 | $642.54 | $1,056,978.30 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 10 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,260 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 1,645 shares of Company stock on September 13, 2021 at prices ranging from $642.00 to $642.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 952 | $641.56 | $610,765.12 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 9 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,905 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 952 shares of Company stock on September 13, 2021 at prices ranging from $641.01 to $641.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 981 | $640.61 | $628,438.41 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 8 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,857 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 981 shares of Company stock on September 13, 2021 at prices ranging from $640.18 to $640.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,260 | $639.45 | $805,707.00 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 7 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,838 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 1,260 shares of Company stock on September 13, 2021 at prices ranging from $639.00 to $639.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,098 | $638.46 | $1,339,489.08 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 6 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,098 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 2,098 shares of Company stock on September 13, 2021 at prices ranging from $638.00 to $638.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 816 | $637.71 | $520,371.36 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 5 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,196 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 816 shares of Company stock on September 13, 2021 at prices ranging from $637.26 to $637.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 816 | $636.64 | $519,498.24 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 4 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,012 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 816 shares of Company stock on September 13, 2021 at prices ranging from $636.08 to $636.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 4,250 | $273.67 | $1,163,097.50 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 3 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.